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Introduction
Current dogma regarding the etiology of hypertension
states that renal abnormalities of sodium handling cause
an increase in blood volume that overwhelms vascular
counter-regulatory responses, resulting in hypertension.
Although it is known that acute changes in vascular mor-
phology and tone can cause an increase in vascular resis-
tance and blood pressure, we have hypothesized that
primary abnormalities of the regulation of vascular
smooth muscle tone can also be an etiology for hyperten-
sion. We have previously demonstrated that disruption of
the leucine zipper targeting domain in PKGIa results in
dysregulation of vasomotor tone and hypertension in the
setting of normal renal function. To directly test the
hypothesis that abnormalities in vasomotor regulation
can be the primary etiology of hypertension, we have
developed and now characterize a novel mouse model
harboring a smooth muscle cell (SMC) specific deletion
of the PKGIa target we identified previously, RGS2, a
GTPase activating protein that inhibits Gq-coupled
G-protein coupled receptor (GPCR) signaling, whose
total body deletion in mice causes hypertension (Tang
et al, Nature Medicine, 2003).
Results
Smooth muscle specific RGS2 knockout mice (RGS2-
SMC-KO) were generated by crossing mice carrying an
RGS2 gene with exons 2 to 5 flanked by LoxP sites with
inducible SMA-CRE-ER
T2 mice. SMC-specific deletion of
RGS2 was induced by tamoxifen administration at the
age of 7 weeks. Cre negative mice treated with tamoxifen
were used as controls. Telemetric monitoring (DSI) of
b l o o dp r e s s u r e( B P )a n dh e a r tr a t e( H R )i nm a l eR G S 2 -
SMC-KO mice showed that these mice have a significant
increase in systolic BP vs. control mice (135 ± 5 mmHg
vs. 122 ± 7 mmHg, respectively. P<0.01) without a conco-
mitant change in HR. The change in BP after challenge
with a bolus injection of the NOS inhibitor L-NAME
(50 mg/kg i.v.) was significantly less in the RGS2-SMC-
KO mice compared to WT mice. (ΔSBP: 38 ± 7 mmHg
vs. 47 ± 3 mmHg, respectively. P<0.001), consistent with
decreased basal endogenous NO signaling. BP responses
to changes in dietary sodium intake in the RGS2-SMC-
KO mice were identical to control mice.
Conclusion
Though further characterization of renal function and
vasomotor regulation in RGS2-SMC-KO mice is ongoing,
the current data demonstrate the presence of hyperten-
sion in these mice, together with normal sodium hand-
ling, supporting the hypothesis that high blood pressure
can arise from a primary abnormality of vascular smooth
muscle cell contractile regulation. These findings, taken
together with the diminished SBP response to L-NAME,
support that endogenous NO signaling, and the activa-
tion of the NO-sGC-PKGI pathway in smooth muscle
cells, are necessary to maintain normal vascular tone and
b l o o dp r e s s u r eb ya t t e n u a ting Gq mediated GPCR con-
strictive signaling.
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